权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Gait and Balance Changes in Chemotherapy Induced Peripheral Neuropathy

化疗引起的周围神经病变的步态和平衡变化

基本信息

批准号：
8784206
负责人：
Ajit Mohan Worthen Chaudhari
金额：
$ 7.7万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-01-01 至 2017-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8784206
关键词：
Activities of Daily Living Affect Area Breast Cancer Patient Cancer Patient Cancer Survivor Chemotherapy-induced peripheral neuropathy Colorectal Cancer Data Development Dose-Limiting Effectiveness Effectiveness of Interventions Elderly Equilibrium European Organization for Research and Treatment of Cancer Exercise Future Gait Goals Health Incidence Individual Intervention Knowledge Laboratories Lead Length Life Malignant Neoplasms Measures Natural History Nerve Paclitaxel Pain Patient Outcomes Assessments Patient Self-Report Patients Peripheral Peripheral Nervous System Diseases Pharmaceutical Preparations Platinum Population Quality of life Quantitative Evaluations Relative (related person)Reporting Research Risk Signs and Symptoms Survivors Symptoms Taxane Compound Testing Time Toxic effect Treatment Effectiveness Treatment Protocols Vinca Alkaloids Walking Width Work base chemotherapy chemotherapy induced neuropathy colon cancer patients diabetic effective therapy experience fall risk falls instrument malignant breast neoplasm neurotoxicity oxaliplatin predictive marker prevent spatiotemporal taxane tool treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity1 of several commonly used classes of chemotherapy drugs. Peripheral neuropathies have been shown to lead to pain, falls, difficulty in walking and performing activities of daily living in many different populations including the elderly, diabetics, and, caner patients. Based on previous data from other groups of patients with peripheral neuropathies, the central hypothesis of our study is that CIPN results in altered gait and balance, similar to what has been observed in elderly and diabetic populations with peripheral neuropathy. To test our hypothesis, we will first characterize the alterations in gait and balance that occur i breast and colorectal cancer patients during chemotherapy with paclitaxel and oxaliplatin agents. Specifically, we will evaluate (1) spatiotemporal gait parameters, including cadence, step length, and step width, and (2) balance parameters, including time-to-contact and 95% ellipse area, using each patient as his/her own control. Subsequently, we will compare the natural history of changes in gait and balance parameters with changes in CIPN status as measured by validated objective and patient-report instruments including the TNS, EORTC CIPN-20 and BPI that are in commonly used in CIPN research. The long-term goal of our research is to reduce the burden of CIPN on cancer patients' mobility and quality of life. The overall objective of this application is to quantify the natural history o functional deficits that occur due to chemotherapy with oxaliplatin and paclitaxel. Completion of this study will establish the feasibility of evaluating balance and gait parameters as predictors o CIPN. If successful, then this will be an easy to implement and objective assessment of CIPN for future assessment of effectiveness of interventions that help mitigate or perhaps even prevent CIPN in breast and colorectal cancer survivors.

描述（由申请人提供）：化疗诱导的周围神经病变（CIPN）是几种常用化疗药物的剂量限制性毒性1。周围神经病变已被证明会导致许多不同人群（包括老年人、糖尿病患者和癌症患者）的疼痛、福尔斯、行走困难和进行日常生活活动。基于来自其他周围神经病变患者组的先前数据，我们研究的中心假设是CIPN导致步态和平衡改变，类似于在患有周围神经病变的老年人和糖尿病人群中观察到的情况。为了验证我们的假设，我们将首先描述乳腺癌和结直肠癌患者在紫杉醇和奥沙利铂化疗期间步态和平衡的变化。具体而言，我们将评估（1）时空步态参数，包括节奏、步长和步长，以及（2）平衡参数，包括接触时间和95%椭圆面积，使用每位患者作为他/她自己的对照。随后，我们将比较步态和平衡参数变化的自然史与CIPN状态变化，这些变化由经验证的客观和患者报告仪器测量，包括CIPN研究中常用的TNS、EORTC CIPN-20和BPI。我们研究的长期目标是减轻CIPN对癌症患者的流动性和生活质量的负担。本申请的总体目的是量化奥沙利铂和紫杉醇化疗引起的功能缺陷的自然史。本研究的完成将确立评估平衡和步态参数作为CIPN预测因子的可行性。如果成功，那么这将是一个容易实施和客观的评估CIPN的干预措施，有助于减轻甚至预防乳腺癌和结直肠癌幸存者的CIPN的有效性的未来评估。